Disclaimer: Important Notice

No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accuracy, completeness or fairness of the information contained in this presentation and no responsibility or liability is accepted for any such information. This presentation does not constitute an offer of securities by the Company and no investment decision or transaction in the securities of the Company should be made solely on the basis of the information contained in this presentation.

This presentation contains certain information which the Company's management believes is required to understand the performance of the Group. However, not all of the information in this presentation has been audited. Further, this presentation includes or implies statements or information that are, or may deemed to be, "forward-looking statements". These forward-looking statements may use forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will" or "should". By their nature, forward-looking statements involve risks and uncertainties and recipients are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's or the Group's actual results and performance may differ materially from the impression created by the forward-looking statements or any other information in this presentation.

The Company undertakes no obligation to update or revise any information contained in this presentation, except as may be required by applicable law or regulation. Nothing in this presentation is intended to be, or intended to be construed as, a profit forecast or a guide as to the performance, financial or otherwise, of the Company or the Group whether in the current or any future financial year.

This presentation and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.

Certain information in this presentation has been extracted from announcements made by the Company and this presentation is not a substitute for reading the Company's announcements in full.
Key Messages

Unique opportunity to invest in an innovative and disruptive UK biotech company

1. **Proprietary, highly disruptive technology**
   Avacta's proprietary Affimer® technology platform serves as a basis for new drug and reagent development and offers **significant technical and commercial benefits** over traditional antibodies.

2. **Huge potential market**
   The global antibody market is worth **$100bn** and is growing at 15% pa.

3. **Considerable uplift opportunity**
   **Significant milestones** should be achieved in the **near future** that would support **considerable valuation uplift** and bring Avacta in line with comparators.

4. **Opportunity to disrupt the established market players**
   The antibody market has considerable amounts of blocking IP. **Affimer® circumvents this blocking IP** and gives new entrants an opportunity to **compete in valuable applications**.

5. **Downside protection through a balanced and sustainable business model**
   Affimer is a **platform technology** capable of generating a continuous pipeline of products. Unlike classic biotech companies Avacta also has **downside protection** from its reagents business which generates **recurring revenue**.
Antibody markets are worth in excess of $100bn despite significant limitations relating to size, structural complexity, cost and fragility.
Clear **commercial and technical benefits** over antibodies

- Smaller, simpler, more robust
- Quicker to develop
- Proprietary with freedom to operate
- Simpler and cheaper to manufacture
- More adaptable
Affimer Business Model

**Licensing** individual Affimer molecules for **therapeutics** and **diagnostics**

**Therapeutics**
- Developing multiple clinical candidates for development and/or licensing to major pharma

**High Value Reagents**
- Royalties from licensing Affimers to research and diagnostic test developers

Affimer® is a **platform technology** not a single asset
$30bn of deals since 2015 – many pre-clinical

(Apr 2016) $685m with $40m upfront in deal for ARG-115X asset

(Aug 2017) Gilead acquires Kite for $11.9bn

(May 2017) up to $115m upfront and success-based payments for PD-L1/LAG3 bispecific

(Jan 2017) $31m upfront and up to $338m in success-based payments for checkpoint inhibitor plus 4 other programs

(Jan 2018) Celgene acquires Juno for $9bn

(May 2015) $0.5m upfront, tens $m in milestone payments for mRNA therapeutic Affimers
Affimer Therapeutics Business

**In-house Pipeline**

- Focus on **immuno-oncology**.
- **Pre-clinical pipeline** leveraging Affimer technical advantages.
- Building out a potentially **transformative pipeline** of I-O assets for **partnering**.
  - Multi-targeting therapies
  - Novel drug conjugates
  - Agonists
- **Biotech partnerships** established and **large pharma in discussion**.

**Partnered Pipeline/Collaborations**

- Moderna
- ONCOSEC
- Tufts University School of Medicine
- Glythera
- FIT BIOTECH
- PhoreMost

© Avacta Group plc
A joint invention with Tufts one of the top US medical schools and cancer centres

- First Affimer TMAC in development:
- Targeting: PD-L1 using Affimers already generated in Avacta’s lead programme
- Linker: Already generated by Tufts
- Warhead: PT-100 already generated by Tufts with substantial clinical data
- Commercials: Avacta has exclusive commercial rights to the TMAC concept and the PD-L1/PT-100 embodiment
- First milestone: in vitro and in vivo data by end of 2019
Building a **recurring revenue stream** from **licensing high value reagents**

- Targeting **high value applications** where antibodies are deficient.
- **Proven technology** with third party validation in numerous applications.
- **Revenue** generating (FY18 £1.2M).
- **Licensing** business model.
- First product development license with a **top three global diagnostics company**.
- Over **25 third party evaluations** ongoing in multiple applications.
- **Sustainable low cost base** of low single digit £m.

### TARGET APPLICATIONS

- **Immuoassays**
- **Bioprocessing**
- **Clinical and Rapid Diagnostics**
- **IHC** (In Development)
Anticipated Near-term Newsflow

• Therapeutics partnering/license deal(s).
• High profile Chief Medical Officer appointment.
• Licensing/supply deals with research/diagnostics companies.
• Additional therapeutics research collaborations.
• Potential for Moderna to take Affimer candidate(s) into clinical development.
• Pre-clinical development milestones for collaborative programmes.
• Candidate selection for anti-PD-L1/LAG-3 bispecific Affimer clinical development.
• Completion of IND enabling studies for anti-PD-L1/LAG-3 bispecific.
Comparators: Therapeutic Platforms

Clinical stage therapeutic platforms are valued at least 10x Avacta’s market capitalisation

- **Molecular Partners** (SWX: MOLN)
  - £372m
  - DARPin
  - Several assets in phase 1/2/3
  - Abicipar in phase 3

- **Pieris** (NASDAQ: PIRS)
  - £220m
  - Anticalins
  - 3 assets in phase 1/1b/2a

- **Ablynx** (EBR: ABLX, NASDAQ: ABLX)
  - £2bn
  - Camelid “Nanobody”
  - Multiple assets in phase 1/2/3 and first product about to receive marketing approval (Caplacizumab)

- **Avacta** (AIM: AVCT)
  - £28m
  - Multiple preclinical assets

*Acquired by Sanofi January 2018 for £3.7bn*
An established **recurring revenue stream** would more than **underpin Avacta’s market capitalisation**

**bioventix**

AIM: BVXP

£150m

Sheep antibodies

- Revenue FY17 £7.25m
- Post-tax profit £4.92m
- Market cap £140m
- PE multiple 28

**Avacta**

AIM: AVCT

£28m

- Paid for evaluations revenue FY18 £1.2m (E)
- First diagnostics license to one of top three global Dx companies 2017
- >25 technology evaluations ongoing
August 2018 Placing

- **Successful placing** August 17, 2018 raised £11.6m to fully fund key commercial and pre-clinical development milestones:
  - Secure significant **drug development partnership(s)**.
  - Build a **substantial pipeline of Affimer therapeutic assets** for partnering.
  - **Grow revenue** through **licensing of Affimer reagents**.
Key Messages

Unique opportunity to invest in an innovative and disruptive UK biotech company

1. **Proprietary, highly disruptive technology**
   Avacta’s proprietary Affimer® technology platform serves as a basis for new drug and reagent development and offers **significant technical and commercial benefits** over traditional antibodies.

2. **Huge potential market**
   The global antibody market is worth **$100bn** and is growing at 15% pa.

3. **Considerable uplift opportunity**
   **Significant milestones** should be achieved in the **near future** that would support **considerable valuation uplift** and bring Avacta in line with comparators.

4. **Opportunity to disrupt the established market players**
   The antibody market has considerable amounts of blocking IP. **Affimer® circumvents this blocking IP** and gives new entrants an opportunity to **compete in valuable applications**.

5. **Downside protection through a balanced and sustainable business model**
   Affimer is a **platform technology** capable of generating a continuous pipeline of products. Unlike classic biotech companies Avacta also has **downside protection** from its reagents business which generates **recurring revenue**.
Thank you